Ardent Health Inc. (ARDT) Next Earnings Date & Expected ±7.8% Move

ARDT scores 69 out of 100 (letter grade C+; verdict label "Roarable Hold — Upper Neutral / Watch for Breakout"). The five pillars are: Fundamental Cash Engine 16/20 (ROIC 10.5%; FCF yield 0%), Whale 13F Flow 14/20 (institutional accumulation and options positioning), Insider Conviction 13/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 11/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet 15/20 (Altman Z 2.5; Piotroski F 7/9; Debt/Equity 0.84). The strongest pillar is the cash engine and balance-sheet forensics, which together support the upper-neutral framing. The weakest pillar is macro regime fit, indicating that the stock's behavior is tied to broader sector and market conditions rather than being independently driven. The FCF yield of 0% in the rating's fundamental pillar sits in tension with the positive reported FCF in the financials section, so an investor should verify how the yield is computed before weighting that pillar heavily. Valuation context from the market data (trailing P/E 12.8, forward P/E 11.9) is not directly scored by the RQD pillars. The rating reflects a "watch for breakout" stance rather than a directional buy or sell signal.

Ardent Health Inc. (ARDT) is a NYSE-listed issuer in the Health Care sector, within the Hospital/Nursing Management industry. Revenue scale is reflected in the SEC financials, which report $6.32B for FY 2025. Further detail on products, payer or patient mix, and geographic footprint is —

Revenue grew from $5.41B (FY 2023) to $6.32B (FY 2025), while net income declined from $210.3M (FY 2024) to $135.8M (FY 2025). Reported operating income is — in every period, so operating margin cannot be meaningfully assessed from this source. Per the market data, net margin is 2.1%, gross and operating margins are listed as 0%, and ROIC is 10.5%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.84. Cash moved from $556.8M to $709.6M and debt from $1.09B to $1.08B over FY 2024–FY 2025.

• 🐂 Primary Bull Case: Revenue grew from $5.41B in FY 2023 to $6.32B in FY 2025 while FCF rose to $470.5M, with a Piotroski F-Score of 7/9 and Altman Z of 2.5 supporting balance-sheet strength. With Fundamental Cash Engine at 16/20 (ROIC 10.5%, FCF yield —) and Institutional Whale Flow at 14/20, sustained execution supports upside toward the top of the $7.71 – $14.99 52-week range.
• 🐻 Primary Bear Case: Net income fell from $210.3M in FY 2024 to $135.8M in FY 2025 and operating income is reported as $0.0M in every period, leaving profitability trajectory unclear. Investors must weigh 12.8x trailing P/E against — operating margins and a 1.00 macro beta if sector demand softens.

Investors should note that the RQD macro-regime pillar (11/20, beta 1.0) indicates sensitivity to sector and market conditions, which is the principal second-order channel the data supports. Specific 2nd-order bottlenecks cannot be identified from the sources provided.

• Key Question #1: Operating income is reported as — in all periods; what is the actual operating margin and profitability trajectory?
• Key Question #2: What were the circumstances and any financial or legal consequences of the former CEO's termination for cause?
• Key Question #3: What is the current institutional, insider, and analyst ownership profile, given that the holders and analyst sections contain no data?